Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells
- Author(s)
- Shin Hwa Lee; Cheol Park; Cheng-Yun Jin; Gi-Young Kim; Sung-Kwon Moon; Jin Won Hyun; Won Ho Lee; Byung Tae Choi; Taeg Kyu Kwon; Young Hyun Yoo; Yung Hyun Choi
- Keimyung Author(s)
- Kwon, Taeg Kyu
- Department
- Dept. of Immunology (면역학)
Institute for Medical Science (의과학연구소)
- Journal Title
- Biomedicine & Pharmacotherapy
- Issued Date
- 2008
- Volume
- 62
- Issue
- 10
- Abstract
- This study was conducted to further elucidate the possible mechanisms by which esculetin, a coumarin compound, exerts its anti-proliferative action on cultured human monocytic leukemia U937 cells. The inhibitory effects of esculetin on cell viability were found to be associated with a G1 arrest in cell cycle progression that was concomitant with an inhibition of cyclin E and an induction of cyclin-dependent kinase (Cdk) inhibitor p21/WAF1/CIP1 in a p53-independent manner. Cells that were treated with esculetin showed increased binding of p21 with Cdk2 and Cdk4 that was paralleled by a marked decrease in the Cdk2 and Cdk4 kinase activities with no change in their expression. We also observed that down-regulation of the phosphorylation of retinoblastoma protein (pRB) by this compound was associated with enhanced binding of pRB and the transcription factor E2F-1. Further investigation showed that inhibition of the extracellular-regulated kinase (ERK) signaling pathway reduced the induction of p21 and the inhibition of pRB phosphorylation and cyclin E expression by esculetin, which in turn overcame the G1 arrest and growth inhibition that was induced by esculetin. These data demonstrate that the ERK pathway participates in p21 induction and subsequently leads to a decrease in the kinase activity of Cdks and inhibition of pRB phosphorylation in esculetin-mediated G1 arrest of U937 cells.
Keywords: Esculetin; U937; G1 arrest; pRB; p21; ERK
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.